Zobrazeno 1 - 10
of 1 292
pro vyhledávání: '"RC254-282"'
Autor:
Yi‐Cheng Pan, Pei‐Yi Chu, Ching‐Chan Lin, Ching‐Yun Hsieh, Wei‐Yu Hsu, Lie‐Fen Shyur, Juan‐Cheng Yang, Wei‐Chao Chang, Yang‐Chang Wu
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1866-1884 (2024)
Bladder cancer poses a significant challenge to chemotherapy due to its resistance to cisplatin, especially at advanced stages. Understanding the mechanisms behind cisplatin resistance is crucial for improving cancer therapy. The enzyme glutathione S
Externí odkaz:
https://doaj.org/article/2b592489dea7445fbc623aa501dcb1dd
Autor:
Anita G. Kansy, Ramy Ashry, Al‐Hassan M. Mustafa, Abdallah M. Alfayomy, Markus P. Radsak, Yanira Zeyn, Matthias Bros, Wolfgang Sippl, Oliver H. Krämer
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1958-1965 (2024)
Mammalian cells replicate ~ 3 × 109 base pairs per cell cycle. One of the key molecules that slows down the cell cycle and prevents excessive DNA damage upon DNA replication stress is the checkpoint kinase ataxia‐telangiectasia‐and‐RAD3‐rela
Externí odkaz:
https://doaj.org/article/3c603aa7f4ed49c783038eaa1696cb4c
Autor:
Sir Harpal Kumar
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1817-1820 (2024)
The reliance on mortality endpoints in cancer screening trials is not always compatible with the need to accelerate progress in outcomes for patient and public benefit. Evaluation of novel cancer screening technologies, such as multi‐cancer early d
Externí odkaz:
https://doaj.org/article/19910d686f134ef8b21dc4f15da346cc
Autor:
Akshatha N. Srinivas, Diwakar Suresh, Prashant M. Vishwanath, Suchitha Satish, Prasanna K. Santhekadur, Saisudha Koka, Divya P. Kumar
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1940-1957 (2024)
Metabolic dysfunction‐associated steatohepatitis‐driven hepatocellular carcinoma (MASH‐HCC) is a global clinical challenge for which there is a limited understanding of disease pathogenesis and a subsequent lack of therapeutic interventions. We
Externí odkaz:
https://doaj.org/article/a307303c0e544c5a8ff9b0d9ad67733c
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1821-1848 (2024)
Chimeric antigen receptor (CAR‐T) cell therapy is a newly developed immunotherapy strategy and has achieved satisfactory outcomes in the treatment of hematological malignancies. However, some adverse effects related to CAR‐T cell therapy have to
Externí odkaz:
https://doaj.org/article/5ddb3b9aaf9a43698be3efd5e0037666
Autor:
Tet Woo Lee, Dean C. Singleton, Julia K. Harms, Man Lu, Sarah P. McManaway, Amy Lai, Moana Tercel, Frederik B. Pruijn, Andrew M. J. Macann, Francis W. Hunter, William R. Wilson, Stephen M. F. Jamieson
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1885-1903 (2024)
Tumour hypoxia promotes poor patient outcomes, with particularly strong evidence for head and neck squamous cell carcinoma (HNSCC). To effectively target hypoxia, therapies require selection biomarkers and preclinical models that can accurately model
Externí odkaz:
https://doaj.org/article/8463ca23a4994262a7d8bf8b809ac374
Autor:
Craig A. Vincent, Silvia Remeseiro
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1849-1852 (2024)
A first‐in‐human trial demonstrated that a vaccine targeting the histone mutation H3K27M can induce an immune response, in a mutation‐specific manner, in patients with diffuse midline glioma. In a recent study by Boschert et al., the same group
Externí odkaz:
https://doaj.org/article/7eb562fca33d4a7cb5338788b4dafa4f
Autor:
Yasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman, Santiago Parpal, Elisabetta Bartolini, Kris Van Moer, Simone Caroline Kleinendorst, Kristine Bilgrav Saether, Lionel Trésaugues, Camilla Silvander, Johan Lindström, Jodi Simeon, Mary Jane Timson, Hikmat Al‐Hashimi, Bryan D. Smith, Daniel L. Flynn, Andrey Alexeyenko, Jenny Viklund, Martin Andersson, Jessica Martinsson, Katja Pokrovskaja Tamm, Angelo De Milito, Bassam Janji
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1904-1922 (2024)
An immunosuppressive tumor microenvironment promotes tumor growth and is one of the main factors limiting the response to cancer immunotherapy. We have previously reported that inhibition of vacuolar protein sorting 34 (VPS34), a crucial lipid kinase
Externí odkaz:
https://doaj.org/article/9dddee620d924c2eb795ae4895e7f6b3
Autor:
Olivier Romito, Aude Lemettre, Aurélie Chantôme, Ophélie Champion, Noémie Couty, Lobna Ouldamer, Nadine Hempel, Mohamed Trebak, Caroline Goupille, Marie Potier‐Cartereau
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1853-1865 (2024)
No data are currently available on the functional role of small conductance Ca2+‐activated K+ channels (SKCa) in ovarian cancer. Here, we characterized the role of SK2 (KCa2.2) in ovarian cancer cell migration and chemosensitivity. Using the select
Externí odkaz:
https://doaj.org/article/9b4055aa053c49139808a9db354ee945
Autor:
Jeon Yeob Jang, Bok‐Soon Lee, Mei Huang, Chorong Seo, Ji‐Hye Choi, Yoo Seob Shin, Hyun Goo Woo, Chul‐Ho Kim
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1923-1939 (2024)
Immune checkpoint blockers (ICBs) targeting programmed cell death protein 1 (PD‐1) have been proven to be an effective first‐line therapy against programmed cell death 1 ligand 1 (PD‐L1; also known as CD274 molecule)‐expressing head and neck
Externí odkaz:
https://doaj.org/article/a704151655bb4d57aa35d4ad6e96c413